• 企業・知財を促進
    • スタートアップ企業一覧
    • IP&技術一覧
  • ヘルプを取得
    • 質問を検索
    • プロジェクトを投稿
    • 専門家Directoryを検索
  • リソース
    • ドキュメントセンター
    • 特許を検索
    • 専門家の記事・ブログ
  • ニュース
    • Tech&IPニュース
  • マイアカウント
  • ログイン
  • 専門家向け

特許

68,018 件
全IP種別
PATENTFIELDで検索
IPを掲載
係属中

Plants modified with mini-c...

In 2006, scientists demonstrated the successful use of telomere truncation in maize plants to produce minichromosomes that could be utilized as a platform for inserting genes into the plant genome[...

係属中

Staphylococcal infection

Staphylococci are species of Gram-positive bacteria that can cause a wide variety of infections in humans and other animals through infection or the production of toxins. Staphylococcal toxins are ...

権利維持

Idiopathic pulmonary fibrosis

diopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease characterized by a progressive decline in lung function.[2][3] The term pulmonary fibrosis means scarring of lung tissue...

係属中

Radiation-induced epithelia...

Radiation-induced epithelial disorders

権利維持

Natural killer T cell

Natural killer T (NKT) cells are a heterogeneous group of T cells that share properties of both T cells and natural killer (NK) cells. Many of these cells recognize the non-polymorphic CD1d molecul...

権利維持

Mucositis

Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract, usually as an adverse effect of chemotherapy and radiotherapy treatment for cancer.[1] Mucos...

権利維持

Egr-1 promoter

Egr-1 promoter

係属中

Remyelination

Remyelination is the process of propagating oligodendrocyte precursor cells to form oligodendrocytes to create new myelin sheaths on demyelinated axons in the CNS. This is a process naturally regul...

係属中

Nanocomposites

Nanocomposite is a multiphase solid material where one of the phases has one, two or three dimensions of less than 100 nanometers (nm), or structures having nano-scale repeat distances between the ...

権利維持

Recombinant polypeptide pro...

Protein production can occur after gene expression. It consists of the stages after DNA has been transcribed to messenger RNA (mRNA). The mRNA is then translated into polypeptide chains, which are ...

権利維持

Liver X receptor agonists

LXR agonists are effective for treatment of murine models of atherosclerosis, diabetes, anti-inflammation, and Alzheimer's disease. Treatment with LXR agonists (hypocholamide, T0901317, GW3965, or ...

権利維持

Nerve tissue injury

Nerve injury is injury to nervous tissue. There is no single classification system that can describe all the many variations of nerve injury. Most systems attempt to correlate the degree of injury ...

権利維持

Polypeptide immobilization

Polypeptide immobilization

係属中

Microfluidics

Microfluidics is a multidisciplinary field intersecting engineering, physics, chemistry, biochemistry, nanotechnology, and biotechnology, with practical applications to the design of systems in whi...

権利維持

Microbe-mediated epithelial...

Microbe-mediated epithelial disorders

権利維持

Ferromagnetic materials

The table on the right lists a selection of ferromagnetic and ferrimagnetic compounds, along with the temperature above which they cease to exhibit spontaneous magnetization (see Curie temperature)...

係属中

Protein A

Protein A is a 42 kDa surface protein originally found in the cell wall of the bacterium Staphylococcus aureus. It is encoded by the spa gene and its regulation is controlled by DNA topology, cellu...

係属中

Inhibiting farnesoid X rece...

The bile acid receptor (BAR), also known as farnesoid X receptor (FXR) or NR1H4 (nuclear receptor subfamily 1, group H, member 4) is a nuclear receptor that is encoded by the NR1H4 gene in humans. ...

係属中

Plant centromere

The centromere is the part of a chromosome that links sister chromatids. During mitosis, spindle fibers attach to the centromere via the kinetochore.[1] Centromeres were first defined as genetic lo...

係属中

Therapeutic delivery

Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect.[1] It ...

  • 最初
  • 前
  • …
  • 1766
  • 1767
  • 1768
  • 1769
  • 1770
  • 1771
  • 1772
  • 1773
  • 1774
  • …
  • 次
  • 最後
イノベーションと知的財産権のためのone-stop shop 今すぐ参加

IP Nexusについて

IP Nexusは、大学・研究機関と連携して新規技術の潜在的なビジネス価値を解明し、技術シーズ・スタートアップ企業を成功へと導かせ、投資家やその他のステークホルダーに貴重なリターンを生み出す知的財産(IP)の商業化企業です。テクノロジーとライフサイエンスにフォーカスしたハイポテンシャルな発明を早期に特定してコマーシャルディレクション、資金調達の専門知識およびマネジメント能力を提供します。アジア地域に特化した専門知識によりアジア地域にフォーカスしています。

免責事項

IP Nexusは、Ask an ExpertとService Marketplaceを提供しています。Ask an ExpertとService Marketplaceは、インタラクティブなオンラインサービスであり、迅速かつ容易にビジネスのための法的相談や法的サービスを見つけることができます。IP Nexusは、法律事務所ではなく、法的助言、法律家の斡旋などの法的サービスを提供することはなく、自ら法的代理を行うことはありません。

コンテンツ

  • 価格
  • よくある質問
  • 知的財産権(IP)の保護
  • 知的財産権(IP)の種類
  • 知的財産権(IP)に関する申し立て
  • 我々のチームについて
  • スタートアップ
  • お問い合せ
  • ブランド資産
  • 利用規約
  • プライバシーポリシー
  • PATENTFIELDで特許を検索

ニュースレター

購読

言語設定

© 2026 IP Nexus. All Rights Reserved.

レポート内容

      問い合わせフォーム